{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006538","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.962179+00:00","generated_at":"2026-06-05T03:49:58.400597+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Monopar reports positive preclinical imaging data for MNPR-101-Lu in pancreatic cancer model","bullets":["SPECT imaging shows high specificity and durable uptake of MNPR-101-Lu in tumor relative to normal tissue in human pancreatic cancer xenograft model.","Data help explain near complete tumor elimination observed after single injection of therapeutic radioisotopes bound to MNPR-101 in prior studies.","MNPR-101-Lu uses Lutetium-177, same therapeutic radioisotope as commercially successful Pluvicto and Lutathera.","Phase 1 dosimetry trial for diagnostic counterpart MNPR-101-Zr recently cleared by HREC in Australia for advanced cancer patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006538","json":"https://secwatch.observer/filing/0001437749-24-006538.json","markdown":"https://secwatch.observer/filing/0001437749-24-006538.md","text":"https://secwatch.observer/filing/0001437749-24-006538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924006538/0001437749-24-006538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924006538/mnpr20240304_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:49:58.400597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}